Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever
This study aimed to investigate the disease characteristics of familial Mediterranean fever (FMF) patients undergoing dose optimisation and discontinuation of canakinumab therapy. A total of 61 patients diagnosed with FMF and using canakinumab for the resistant disease were enrolled on this retrospe...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434546/ https://www.ncbi.nlm.nih.gov/pubmed/36048189 http://dx.doi.org/10.1007/s00296-022-05199-w |